Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
endothelial progenitor cell-derived exosomes
- Development stage
- Phase 4
- Lead developer
- Rejuvion Bio
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Topical, Subcutaneous
01
Overview
RejuvionBio's endothelial progenitor cell (EPC)-derived exosomes are a preclinical exosome-based therapy developed for regenerative aesthetics, specifically targeting skin rejuvenation, hair restoration, and anti-aging. These exosomes are isolated from human EPCs and are characterized by the expression of CD81 and CD9 markers. They function as delivery vehicles for a complex cargo of growth factors and signaling proteins, including vascular endothelial growth factor (VEGF), transforming growth factor alpha (TGF-α), transforming growth factor beta 1 (TGF-β1), platelet-derived growth factor AA (PDGF-AA), insulin, and insulin-like growth factor-binding proteins (IGFBP 1-6). By delivering these factors to target tissues, the therapy aims to stimulate angiogenesis, promote fibroblast proliferation, and enhance the production of extracellular matrix components, thereby facilitating tissue repair and revitalization.
- Brand names
- Exosomes
- Other names
- EPC-derived exosomesRejuvionBio Exosomes
02
Targets
THBS1 (Thrombospondin-1)
Beyond the preview
Go deeper on endothelial progenitor cell-derived exosomes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on endothelial progenitor cell-derived exosomes.